The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab

CheadleE.J.; SidonL.; DovediS.J.; MelisM.H.M.; AlduaijW.; IllidgeT.M.; HoneychurchJ.

首页> 外文期刊>British Journal of Haematology >The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab

【24h】

The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab

机译：与I型利妥昔单抗相比，II型抗CD20单克隆抗体诱导的免疫原性细胞死亡具有机理上的差异

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The anti-CD20 monoclonal antibody (mAb) rituximab has improved outcomes for patients across a range of B-cell malignancies and catalysed the development of a number of other novel anti-CD20 mAb, including the type II anti-CD20 antibody GA101 (Obinutuzumab). GA101 is glycoen-gineered to enhance antibody-dependent cellular cytotoxicity (ADCC) and binds to the CD20 antigen in a fundamentally different way to rituximab to initiate direct Programmed Cell Death (PCD) (Niederfellner et al, 2011) through a novel pathway that is non-apoptotic and dependent on actin rearrangement, lysosomal permeabilisation and reactive oxygen species (ROS) generation via NADPH oxidase and independently of glutathione pathway (Honeychurch et al, 2012).

机译：抗CD20单克隆抗体（mAb）利妥昔单抗改善了一系列B细胞恶性肿瘤的患者预后，并催化了许多其他新型抗CD20 mAb的发展，包括II型抗CD20抗体GA101（Obinutuzumab）。 GA101经过糖蛋白化处理，增强了抗体依赖性细胞的细胞毒性（ADCC），并以与利妥昔单抗根本不同的方式与CD20抗原结合，从而通过一种新颖的途径引发了直接程序性细胞死亡（PCD）（Niederfellner et al，2011）。非凋亡的并且依赖于肌动蛋白重排，溶酶体通透性和经由NADPH氧化酶生成的活性氧（ROS），并且独立于谷胱甘肽途径（Honeychurch等，2012）。

著录项

来源
《British Journal of Haematology》 |2013年第6期|共4页
作者
CheadleE.J.; SidonL.; DovediS.J.; MelisM.H.M.; AlduaijW.; IllidgeT.M.; HoneychurchJ.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词
CD20; Cell death; DAMP; Lymphoma; Monoclonal antibody;

机译：CD20;细胞死亡;DAMP;淋巴瘤;单克隆抗体;

相似文献

外文文献
中文文献
专利

1. The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab [J] . CheadleE.J., SidonL., DovediS.J., British Journal of Haematology . 2013,第6期

机译：与I型利妥昔单抗相比，II型抗CD20单克隆抗体诱导的免疫原性细胞死亡具有机理上的差异
2. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. [J] . Beers SA, Chan CH, James S, Blood: The Journal of the American Society of Hematology . 2008,第10期

机译：II型（tositumomab）抗CD20单克隆抗体在B细胞耗竭时执行I型（rituximab样）试剂，而不考虑补体激活。
3. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. [J] . Alduaij W, Ivanov A, Honeychurch J, Blood: The Journal of the American Society of Hematology . 2011,第17期

机译：新型II型抗CD20单克隆抗体（GA101）在B细胞恶性肿瘤中引起同型粘附和依赖肌动蛋白的溶酶体介导的细胞死亡。
4. An Envelop-Type Gene Nanocomplex with Encapsulated Monoclonal Antibodies for Target Therapy of Hepatocellular Carcinoma [C] . Wang Jinlei, Shen Jie, Hu Qinglian, World biomaterials congress . 2012

机译：信封型基因纳米复合物与封装的单克隆抗体对肝细胞癌的靶向治疗
5. A novel type of cell death of lymphocytes induced by a monoclonal antibody against cell surface antigens without participation of complement利用統計を見る [D] . Matsuoka Shuji 1993

机译：没有补体参与的针对细胞表面抗原的单克隆抗体诱导的新型淋巴细胞细胞死亡
6. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent lysosome-mediated cell death in B-cell malignancies [O] . Waleed Alduaij, Andrei Ivanov, Jamie Honeychurch, -1

机译：新型II型抗CD20单克隆抗体（GA101）引起B细胞恶性肿瘤的同型粘附和依赖肌动蛋白的溶酶体介导的细胞死亡
7. The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab [O] . Cheadle, Eleanor J., Sidon, Lauren, Dovedi, Simon J., 2013

机译：与I型利妥昔单抗相比，II型抗CD20单克隆抗体对免疫原性细胞死亡的诱导具有机械差异

The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab

摘要

著录项

相似文献

相关主题

期刊订阅